Investing after Pfizer’s flop - 3 strategies
August 27th, 2008NEW YORK (Money) — Pfizer’s decision to suspend tests of its latest drug for the treatment of high cholesterol underscores the key problem facing most large pharmaceutical companies. Once a drugmaker has reached a certain size, it’s an enormous challenge to generate new blockbusters fast enough to maintain a high growth rate.
Posted in Legal Questions |